Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2023 | mAbs in MS: where do they fit into the pathophysiology of MS?

Augusto A. Miravalle, MD, FAAN, University of Colorado School of Medicine, Aurora, CO, discusses the impact of monoclonal antibodies in multiple sclerosis (MS) therapy. These antibodies have not only shown the highest efficacy in traditional clinical outcomes but also helped in understanding the role of certain targets in the pathophysiology of MS. Dr Miravalle mentions the initial success of natalizumab, which blocks a critical component in the adhesion pathway for auto-reactive cells entering the CNS and alemtuzumab, which affects both B and T-cell compartments and can lead to the development of autoimmunity. Finally, anti-B-cell therapies, such as ocrelizumab and ofatumumab, are becoming the gold standard of care in MS treatment. These therapies primarily work by depleting B cells. This interview took place at the American Academy of Neurology Annual Meeting 2023 in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Dr Miravalle received consulting honoraria, speaker honoraria and/or research funding from: Alexion, EMD Serono, Genentech, BMS, Horizon, Novartis, Biogen, MF Foundation, MSAA, CanDo MS, American Academy of Neurology.